scholarly journals ARIPIPRAZOLE LONG-ACTING INJECTABLE FOR AN ELDERLY PATIENT WITH DELUSIONAL DISORDER AND MILD DEMENTIA

2021 ◽  
Vol 33 (3) ◽  
pp. 376-377
Author(s):  
I-Chun Lee ◽  
◽  
Yu-Chih Shen ◽  
◽  
Keyword(s):  
Elderly Patient ◽  
Delusional Disorder ◽  
Mild Dementia ◽  
Long Acting

Psychiatrists’ opinion on treatment adherence in Delusional Disorder

2016 ◽  
Vol 33 (S1) ◽  
pp. S570-S570
Author(s):  
B. Girela Serrano ◽  
L. Aguado Bailón ◽  
P. Calvo ◽  
J.E. Muñoz Negro ◽  
J. Cervilla Ballesteros
Keyword(s):  
Treatment Adherence ◽  
Health Care Services ◽  
Delusional Disorder ◽  
Poor Adherence ◽  
Adherence To Treatment ◽  
Care Services ◽  
Active Compliance ◽  
Competing Interest ◽  
Long Acting ◽  
High Level

IntroductionDelusional Disorder (DD) F22 is a disease with low prevalence, probably underdiagnosed by clinical specialists due to the high level of functionality, low awareness of disease, low deterioration of patients and poor adherence to prescribed treatment. Adherence to treatment is considered to be one of the major difficulties that stand in the way of the treatment of DD. The present paper assessed psychiatrists’ opinion of the adherence to treatment of patients with DD.Material and methodsA self-administered survey was conducted on a sample of psychiatrists proceeding on a wide array of mental health care services. Participants provided their opinions regarding adherence to treatment. Descriptive statistics were subsequently calculated with SPSS.ResultsIn the opinion of our participants none of the patients have an active compliance of the treatment, 36% consider that the participation is partial or passive. It is also estimated that 57.5% reject the treatment but not totally and 6.5% believe that rejection is absolute.ConclusionsLiterature informs of the association of poor adherence to treatment and little or no improvement of patients, suggesting the need to address the lack of compliance and adherence to treatment as a crucial aspect to improve the prognosis of DD. To address this problem Long Acting Injections (LAIs) of Atypical Antipsychotics are postulated to be a plausible solution as a good treatment strategy. In order to improve the clinical practice in DD and obtain information for further effectiveness we emphasize the need of implementing clinical studies.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals THE ROLL OF LONG ACTING ANTIPSYCHOTIC DEPOT IN ACHIEVING CLINICAL INSIGHT IN DELUSIONAL DISORDER

2019 ◽  
Author(s):  
Joana Miranda ◽  
Rafael Araújo ◽  
Mafalda Barbosa ◽  
Luís Santos Silva ◽  
Joana Melim ◽  
...  
Keyword(s):  
Delusional Disorder ◽  
Long Acting

A case of delusional disorder

2017 ◽  
Vol 41 (S1) ◽  
pp. s828-s828
Author(s):  
O. Porta Olivares ◽  
M. Juncal Ruiz ◽  
B. Fernández Abascal Puente ◽  
M. Gómez Revuelta ◽  
M. Pérez Herrera ◽  
...  
Keyword(s):  
Therapeutic Relationship ◽  
Psychiatric Treatment ◽  
Delusional Disorder ◽  
Psychotic Symptoms ◽  
First Line ◽  
Behavioral Disturbances ◽  
Competing Interest ◽  
Long Acting ◽  
The Right ◽  
First Line Treatment

IntroductionFunctioning of patients with delusional disorder may be impaired, particularly if the delusional thinking is chronic rather than episodic. They refuse to characterize their beliefs as false and view opposing views with surprise, if not hostility and disdain, dismissing or ignoring them, and continuing their struggle to find resolution or restitution for the wrongs they have endured or the illnesses from which they suffer. They typically reject and often resent the suggestion that they are mentally compromised. They are a difficult group to engage clinically, often refusing to meet with a clinician about their delusions and/or to take medication. The first-line treatment of delusional disorder is antipsychotic medication rather than other clinical interventions. Patients with the disorder often reject psychiatric treatment, it is particularly important that medication be prescribed in the context of a therapeutic relationship that includes support, education, encouragement of healthier pursuits, and discouragement of damaging, delusion-inspired actions.MethodsWe describe a case of a 55-year-old woman with a delusional disorder that was diagnosed 4 years before. The supervision of the right take of the treatment was not possible and the intensity of behavioral disturbances increased. Then we started the treatment with long-acting injectable aripiprazole.ResultsWithin the 4 months following the start of treatment, her mental state improved by attenuation of psychotic symptoms.ConclusionsLong-acting aripiprazole could be an effective tool for treatment of psychotic symptoms in patients with no insight and difficulties to check the proper treatment take.Disclosure of interestThe authors have not supplied their declaration of competing interest.

P-1084 - Efficacy of long-acting injectable risperidone in delusional disorder: an open-label, naturalistic and prospective study

2012 ◽  
Vol 27 ◽  
pp. 1
Author(s):  
A. Gonzalez Rodriguez ◽  
O. Molina Andreu ◽  
M.L. Imaz Gurrutxaga ◽  
A. Pons Villanueva
Keyword(s):  
Prospective Study ◽  
Delusional Disorder ◽  
Open Label ◽  
Long Acting

scholarly journals 65 A Retrospective Study of Aripiprazole Long-acting Once-Monthly Introduction Patterns in Galicia

CNS Spectrums ◽  
2019 ◽  
Vol 24 (1) ◽  
pp. 210-210
Author(s):  
Rebeca Méndez Iglesias ◽  
Daniel Núñez Arias
Keyword(s):  
Mental Health ◽  
Bipolar Disorder ◽  
Clinical Trials ◽  
Psychotic Disorder ◽  
Schizoaffective Disorder ◽  
Delusional Disorder ◽  
Average Dose ◽  
Compulsive Disorder ◽  
Long Acting ◽  
Switching Strategies

AbstractBackgroundAntipsychotic drug treatment is a key component of multiple psychiatric treatment algorithms. Second-generation long-acting injectable antipsychotics (LAIs) have been shown to improve adherence in numerous clinical trials. Patients who can benefit from LAIs therapy can be treated with aripiprazole long acting once-monthly (AOM). However the nature of the introduction patterns of AOM is not well characterized in clinical practice.MethodsA retrospective observational study of AOM introduction was conducted on 157 patients aged 18–75 years-old (95 males, 62 females) who were initiated on AOM treatment between January 2017 – December 2017 in two independent Mental Health Units in the autonomous region of Galicia (Spain). An analysis of the different trends in switching strategies and its adaptation to the prescribing information was carried out. Results were compared between different dose treatment plans and a comparison between inpatients and outpatients’ outcomes was also undertaken. Additional data regarding off-label use was obtained from the sample.ResultsThe sample was composed of 157 patients: 31% diagnosed of Schizophrenia (n=48), 14% Schizoaffective Disorder (n=22), 21% Delusional Disorder (n=33), 17% Bipolar Disorder (n=27), 10% Brief Psychotic Disorder (n=15), 4% Psychotic Disorder Not Specified (n=6), 2% Obsessive-Compulsive Disorder (n=3), 2% Paranoid Personality Disorder (n=3). Regarding the location of the first dose administration: 44% (n=69) were administered in an Acute Psychiatric Inpatient Unit, 44% (n=65) were administered in Mental Health Outpatient Clinics, 11% (n=18) in Psychiatric Day Hospitals and 3% (n=5), in Assertive Community Treatment Programs. 74% (n=116) of patients received an initial dose of 400mg of AOM whereas 26% (n=41) were given 300mg of AOM. The previous antipsychotic was aripiprazole orale (OA) in 61% (n=96) of the cases. The most frequent switch between LAIs was “immediate switch” and in the switch between orale antipsychotics and AOM “tapering and overlap” was found to be the most common pattern. The average dose was 20mg/day in all groups except for patients diagnosed with Delusional Disorder (15mg/day). The average duration of treatment with OA after the first dose was: 32days for patients with Schizophrenia, 23days for Delusional Disorder, 30days for Bipolar Disorder and 19days in Schizoaffective Disorder.ConclusionsOur analysis identified two main patterns of drug switching, the most frequent being “tapering and overlap” in oral treatment, followed by “immediate switch” in patients treated with LAIs.Although our patients are unlike many of those enrolled in clinical trials, the present study indicates that the predominant switching strategies conforms with the Safety Data Sheet.

EPA-0235 – Effectiveness of long-acting injectable antipsychotics (pplai and rlai) in the treatment of delusional disorder with non-prominent hallucinations

2014 ◽  
Vol 29 ◽  
pp. 1
Author(s):  
A. González-Rodríguez ◽  
O. Molina-Andreu ◽  
R. Penadés ◽  
M. Bernardo Arroyo ◽  
R. Catalán
Keyword(s):  
Delusional Disorder ◽  
Long Acting

Successful Treatment of Delusional Disorder With Aripiprazole Long-Acting Injection

2018 ◽  
Vol 38 (4) ◽  
pp. 400-402 ◽  
Author(s):  
Lauren A. Diefenderfer ◽  
Shelby E. Lang ◽  
Maheshkumar Patel
Keyword(s):  
Successful Treatment ◽  
Delusional Disorder ◽  
Long Acting

Combination of Inhaled Corticosteroid and Bronchodilator-Induced Delirium in an Elderly Patient With Lung Disease

2013 ◽  
Vol 27 (1) ◽  
pp. 79-83 ◽  
Author(s):  
Jason M. Moss ◽  
Debra W. Kemp ◽  
Jamie N. Brown
Keyword(s):  
Elderly Patient ◽  
Health Care Providers ◽  
Systemic Absorption ◽  
Reasonable Assumption ◽  
Chronic Obstructive ◽  
Care Providers ◽  
Elderly Male ◽  
Obstructive Pulmonary Disease ◽  
Patients At Risk ◽  
Long Acting

Steroid psychosis has been well described with oral glucocorticoids, however, our search of the literature did not identify an association between delirium and the combination of inhaled glucocorticoids and long-acting beta-agonists. We describe the occurrence of delirium with the combination of an inhaled glucocorticoid and bronchodilator. An elderly male described confusion and hallucinations within 1 week after initiation of budesonide/formoterol for chronic obstructive pulmonary disease. The combination inhaler was discontinued with resolution of symptoms. Several weeks later, the patient was hospitalized and restarted on the combination inhaler. The patient was alert and oriented on admission, however, confusion and hallucinations progressed throughout his hospital stay. The combination inhaler was discontinued and his confusion and hallucinations resolved by discharge. The temporal relationship of these events and a probable Naranjo association allows for reasonable assumption that the use of the budesonide/formoterol combination inhaler caused or contributed to the occurrences of delirium in this elderly patient. The onset of delirium was likely due to the systemic absorption of the glucocorticoid from lung deposition, complicated in an individual with several predisposing risk factors for delirium. Health care providers should be aware of this potential adverse drug reaction when prescribing inhaled medications to older patients at risk for delirium.

Sign in / Sign up

Export Citation Format

Share Document